The Discounted Cash Flow (DCF) valuation of Denali Therapeutics Inc (DNLI) is (170.27) USD. With the latest stock price at 22.97 USD, the upside of Denali Therapeutics Inc based on DCF is -841.3%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 6.9% - 8.5% | 7.7% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (328.98) - (116.22) | (170.27) |
| Upside | -1532.2% - -606.0% | -841.3% |